Van Strum & Towne Inc. Has $6.98 Million Holdings in Johnson & Johnson $JNJ

Key Points

• Van Strum & Towne Inc. reduced its holdings in Johnson & Johnson by 3.8% in the second quarter, now owning 45,707 shares valued at approximately $6.98 million.
• Recent insider transactions include EVP Jennifer L. Taubert selling 56,471 shares worth over $10 million, reducing her stake by 24.08%.
• Analysts have upgraded Johnson & Johnson with target prices rising to between $192.94 and $213.00, reflecting a consensus rating of "Moderate Buy."

Van Strum & Towne Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,707 shares of the company's stock after selling 1,790 shares during the period. Johnson & Johnson accounts for 2.2% of Van Strum & Towne Inc.'s holdings, making the stock its 14th biggest holding. Van Strum & Towne Inc.'s holdings in Johnson & Johnson were worth $6,982,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $35,000. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at $48,000. Finally, von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the first quarter valued at $49,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 0.1%

NYSE:JNJ opened at $190.88 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a 50-day moving average of $178.88 and a 200-day moving average of $163.97. The company has a market cap of $459.71 billion, a PE ratio of 20.42, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $192.10.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of Johnson & Johnson from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, October 8th. Citigroup boosted their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a "buy" rating in a report on Tuesday, October 7th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Bank of America boosted their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.